Fluoroquinolone prophylaxis: A word of caution

Leukemia and Lymphoma

Volumn 52, Issue 1, 2011, Pages 5-6

  Lingaratnam, Senthil ^a   Thursky, Karin A ^a,b,c   Slavin, Monica A ^a,c,d  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE; EXTENDED SPECTRUM BETA LACTAMASE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; BACTERIAL MUTATION; CLOSTRIDIUM DIFFICILE; COAGULASE NEGATIVE STAPHYLOCOCCUS; DRUG EFFICACY; ESCHERICHIA COLI; FEBRILE NEUTROPENIA; HEALTH CARE POLICY; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; NOTE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL (TOPIC); VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA, NON-HODGKIN; NEUTROPENIA; PROGNOSIS;

EID: 78651317165     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.527408     Document Type: Note

References (12)

1. Ng ES-T, Liew Y, Earnest A, Koh LP, Lim S-W, Hsu LY. Audit of fluoroquinolone prophylaxis against chemotherapy-induced febrile neutropenia in a hospital with highly prevalent fluoroquinolone resistance. Leuk Lymphoma 2011;52:133-135.
2. Gomez L, Garau J, Estrada C, et al. Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with a high prevalence of ciprofloxacin-resistant Escher-ichia coli. Cancer 2003;97:419-424.
3. Kern WV, Stein-Bauert M, Pritzkow A, et al. Fluoroquinolone prophylaxis in haematology-oncology patients-is it still useful? Clin Microbiol Infect 2009;15(Suppl. 4):Abstract O299.
4. Nys S, Okeke IN, Kariuki S, Dinant GJ, Driessen C, Stobberingh EE. Antibiotic resistance of faecal Escherichia coli from healthy volunteers from eight developing countries. J Antimicrob Chemother 2004;54:952-955.
5. Gafter-Gvili A, Paul M, Fraser A, Leibovici L. Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. J Antimicrob Chemother 2007;59:5-22.
6. Baden LR. Prophylactic antimicrobial agents and the importance of fitness. N Engl J Med 2005;353:1052-1054.
7. Therriault BL, Wilson JW, Barreto JN, Estes LL. Characterization of bacterial infections in allogeneic hematopoietic stem cell transplant recipients who received prophylactic levoflox-acin with either penicillin or doxycycline. Mayo Clin Proc 2010;85:711-718.
8. Monnet DL, MacKenzie FM, Lopez-Lozano JM, et al. Antimicrobial drug use and methicillin-resistant Staphylococ-cus aureus, Aberdeen, 1996-2000. Emerg Infect Dis 2004;10:1432-1441.
9. Cattaneo C, Quaresmini G, Casari S, et al. Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution. J Antimicrob Chemother 2008;61:721-728.
10. Pépin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clos-tridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41:1254-1260.
11. Segal BH, Freifeld AG, Baden LR, et al. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw 2008;6:122-174.
12. Ortega M, Marco F, Soriano A, et al. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. J Antimicrob Chemother 2009;63:568-574.